According to Catalent's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.4559. At the end of 2023 the company had a P/S ratio of 1.98.
Year | P/S ratio | Change |
---|---|---|
2023 | 1.98 | 16.31% |
2022 | 1.70 | -66.69% |
2021 | 5.11 | 3.35% |
2020 | 4.95 | 63.79% |
2019 | 3.02 | 65.48% |
2018 | 1.82 | -23.1% |
2017 | 2.37 | 33.8% |
2016 | 1.77 | 4.41% |
2015 | 1.70 | -9.11% |
2014 | 1.87 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Supernus Pharmaceuticals
SUPN | 2.60 | 5.89% | ๐บ๐ธ USA |
Jazz Pharmaceuticals JAZZ | 1.80 | -26.71% | ๐ฎ๐ช Ireland |
Aerie Pharmaceuticals AERI | 3.52 | 43.43% | ๐บ๐ธ USA |
Intercept Pharmaceuticals
ICPT | 2.50 | 1.86% | ๐บ๐ธ USA |